VI
AXSM icon

Versor Investments’s Axsome Therapeutics AXSM Stock Holding History

Versor Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,615
Closed -$2.29M – 709
2025
Q1 		$2.29M Buy
+19,615
New +$2.23M 0.37% 34
2024
Q4 		– Sell
-8,807
Closed -$791K – 756
2024
Q3 		$791K Buy
+8,807
New +$769K 0.13% 269

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Versor Investments's AXSM Position: Q2 2025 in Review

Versor Investments sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 19,615 shares — an estimated $2.29M sold.

Versor Investments first reported a position in AXSM in Q3 2024 and held it in 2 quarters. The position peaked at $2.29M in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Versor Investments reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Versor Investments sold 19,615 Axsome Therapeutics shares in Q2 2025, an estimated $2.29M.
  • Versor Investments first reported a position in Axsome Therapeutics in Q3 2024 and held it in 2 quarters.
  • Versor Investments's Axsome Therapeutics position peaked at $2.29M in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Versor Investments's 13F filing for Q2 2025, filed 5 Aug 2025.